phentermine has been researched along with n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Addy, C; Chodakewitz, J; Johnson-Levonas, AO; Jumes, P; Li, H; Li, S; Maes, A; Rosko, K; Stoch, SA; Wagner, JA | 1 |
| Addy, C; Chakraborty, B; Chen, N; Chodakewitz, J; Dunbar, S; Maes, A; Rosko, K; Schoedel, KA; Sellers, EM; Stoch, SA; Wagner, J | 1 |
2 trial(s) available for phentermine and n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
| Article | Year |
|---|---|
Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
Topics: Adolescent; Adult; Amides; Anti-Obesity Agents; Blood Pressure; Drug Administration Schedule; Drug Interactions; Drug Inverse Agonism; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Middle Aged; Phentermine; Pyridines; Receptor, Cannabinoid, CB1 | 2009 |
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
Topics: Adult; Amides; Behavior, Addictive; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Drug Inverse Agonism; Drug Users; Female; Humans; Male; Marijuana Abuse; Middle Aged; Neuropsychological Tests; Phentermine; Psychomotor Performance; Pulse; Pyridines; Receptor, Cannabinoid, CB1 | 2012 |